5-((5-Chloro-2-((pyridin-3-ylmethyl)amino)pyrimidin-4-yl)-amino)-1,3-dihydro-2H-indol-2-one

ID: ALA4077392

Chembl Id: CHEMBL4077392

PubChem CID: 137348674

Max Phase: Preclinical

Molecular Formula: C18H15ClN6O

Molecular Weight: 366.81

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1Cc2cc(Nc3nc(NCc4cccnc4)ncc3Cl)ccc2N1

Standard InChI:  InChI=1S/C18H15ClN6O/c19-14-10-22-18(21-9-11-2-1-5-20-8-11)25-17(14)23-13-3-4-15-12(6-13)7-16(26)24-15/h1-6,8,10H,7,9H2,(H,24,26)(H2,21,22,23,25)

Standard InChI Key:  MUSYPBPUEKXCSS-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4077392

    ---

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SUD4 (402 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Farage (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DOHH-2 (352 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OCI-Ly7 (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Toledo (130 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L02 (4864 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCM460 (247 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PNT1A (47 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 366.81Molecular Weight (Monoisotopic): 366.0996AlogP: 3.38#Rotatable Bonds: 5
Polar Surface Area: 91.83Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.41CX Basic pKa: 5.30CX LogP: 2.45CX LogD: 2.44
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.64Np Likeness Score: -1.71

References

1. Kamada Y, Sakai N, Sogabe S, Ida K, Oki H, Sakamoto K, Lane W, Snell G, Iida M, Imaeda Y, Sakamoto J, Matsui J..  (2017)  Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.,  60  (10): [PMID:28471657] [10.1021/acs.jmedchem.7b00313]
2. Guo W, Xing Y, Zhang Q, Xie J, Huang D, Gu H, He P, Zhou M, Xu S, Pang X, Liu M, Yi Z, Chen Y..  (2020)  Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth.,  63  (2): [PMID:31895575] [10.1021/acs.jmedchem.9b01618]
3. Teng M, Ficarro SB, Yoon H, Che J, Zhou J, Fischer ES, Marto JA, Zhang T, Gray NS..  (2020)  Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.,  11  (6): [PMID:32551010] [10.1021/acsmedchemlett.0c00111]
4. Gu H, He J, Li Y, Mi D, Guan T, Guo W, Liu B, Chen Y..  (2022)  B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.,  65  (23.0): [PMID:36441945] [10.1021/acs.jmedchem.2c01433]
5. Ai Y, Hwang L, MacKerell AD, Melnick A, Xue F..  (2021)  Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.,  64  (8.0): [PMID:33844535] [10.1021/acs.jmedchem.0c01686]

Source